https://www.live-feeds.com/feed/novartis-ceo-keeps-faith-in-avidity-deal-despite-taking-1-9b-hit-from-del-desiran-failContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-ceo-keeps-faith-in-avidity-deal-despite-taking-1-9b-hit-from-del-desiran-failhttps://www.live-feeds.com/feed/novartis-ceo-keeps-faith-in-avidity-deal-despite-taking-1-9b-hit-from-del-desiran-fail#u165010Sat, 31 Oct 2026 07:21:35 +0000Novartis CEO Vas Narasimhan remains confident in the company's $12 billion acquisition of Avidity Biosciences despite a $1.9 billion impairment charge stemming from the Phase 3 failure of del-desiran. The HARBOR trial in myotonic dystrophy type 1 missed its primary endpoint for hand function improvement. Despite the setback and overall drug trial setbacks totaling $2.2 billion, Novartis lifted its annual profit guidance. The company noted signals in secondary endpoints and is evaluating another pivotal study for the treatment.Why it mattersThe impairment reflects additional time and resou